Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European ...

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

Natco Pharma launched a cheaper generic version of the cancer drug ‘Pomalyst’ in the U.S. to treat multiple myeloma, making ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms — pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled ...

In June 2025, we reported on a study that showed long-term survival with undetectable disease in heavily pretreated multiple myeloma. The results not only added fresh evidence of efficacy for CAR ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

After Maine's Total Weather chief meteorologist Roger Griswold shared his multiple myeloma diagnosis, we're looking at what ...